Gene Therapy for Fanconi Anemia, Complementation Group A

Sponsor

Rocket Pharmaceuticals Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04248439

Collaborator

(none)

Enrollment

Locations

Arm

34.5

Anticipated Duration (Months)

2.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.

Condition or Disease	Intervention/Treatment	Phase
Fanconi Anemia Complementation Group A	Biological: RP-L102	Phase 2

Detailed Description

This is a pediatric open-label Phase II clinical trial to assess the efficacy of a hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with FA-A.

Enriched CD34+ hematopoietic stem cells will be transduced ex vivo with the therapeutic lentiviral vector and infused via intravenous infusion following transduction without any prior conditioning.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

5 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A

Actual Study Start Date :

Jul 15, 2020

Anticipated Primary Completion Date :

Jun 1, 2022

Anticipated Study Completion Date :

Jun 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: RP-L102 RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene	Biological: RP-L102 CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene

Arm

Intervention/Treatment

Experimental: RP-L102

RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene

Biological: RP-L102

CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene

Outcome Measures

Primary Outcome Measures

Phenotypic correction of bone marrow colony forming units after infusion of RP-L102 [3 years]
During months 12-36 post-infusion, the survival of bone marrow colony forming units to 10nM mitomycin C (MMC) increases to over or equal to 10% with respect to values determined at baseline (pretreatment evaluation).

Secondary Outcome Measures

Phenotypic correction of T-lymphocytes in peripheral blood after infusion of RP-L102 [3 years]
Assessment of the percentage of peripheral blood T-cells with diepoxybutane (DEB)-induced chromosomal aberrations
Engraftment of gene-corrected hematopoietic cells after infusion of RP-L102 [3 years]
The level of gene marking of the FANCA-lentiviral vector (LV) provirus in total peripheral blood cells is at least 0.1 vector copy number (VCN) in peripheral blood cells during months 12-36 post-infusion
Prevention or rescue of bone marrow failure after infusion of RP-L102 [3 years]
Assessment of the need for treatment of bone marrow failure 6-36 months post-infusion.

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Fanconi anemia as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
Patients of the complementation group FA-A
Minimum age: 1 year and a minimum weight of 8 kg
At least 30 CD34+ cells/μL are determined in one bone marrow (BM) aspiration within 3 months prior to CD34+ cell collection OR (see subsequent criterion)
If the number of CD34+ cells/ μL in BM is in the range of 10-29, peripheral blood (PB) parameters should meet two of the three following criteria:

Hemoglobin: ≥11g/dL
Neutrophils: ≥900 cells/μL
Platelets: ≥60,000 cells/μL

Provide informed consent in accordance with current legislation
Women of childbearing age must have a negative urine pregnancy test at the baseline visit, and accept the use of an effective contraception method during participation in the trial

Exclusion Criteria:

Subjects with an available and medically eligible HLA-identical sibling donor.
Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the subject commences the stem cell mobilization/collection procedures of the clinical trial.
Subjects with somatic mosaicism associated with stable or improved counts in all PB cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease (≥1 NCI CTCAE grade) in at least one blood lineage over time must be documented to enable eligibility, as should <5% resistance of bone marrow colony forming cells (CFCs) to 10nM MMC; whenever possible potential mosaicism should also be evaluated by gene sequencing of MMC-resistant CFCs).
Lansky performance status ≤60%.
Any concomitant disease or condition that, in the opinion of the Principal Investigator, renders the subject unfit to participate in the study.
Pre-existing sensory or motor impairment ≥grade 2 according to the criteria of the NCI.
Pregnant or breastfeeding women.
Hepatic dysfunction as defined by either:

Bilirubin >3.0 × the upper limit of normal (ULN) or
Alanine aminotransferase (ALT) > 5.0 × ULN or
Aspartate aminotransferase (AST) > 5.0 × ULN

For subjects with bilirubin, ALT or AST above ULN, a workup to identify the etiology of liver abnormality should be conducted prior to confirmation of eligibility as stipulated in exclusion criterion 5, including evaluation of viral hepatitis, iron overload, drug injury or other causes.

Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
Pulmonary dysfunction as defined by either:

Need for supplemental oxygen during the prior 2 weeks in absence of acute infection or
Oxygen saturation by pulse oximetry <90%.

Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years.
Subject is receiving androgens (i.e. danazol, oxymetholone).
Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure.